Altimmune

Phase A — Understand the business

Lens 1 · Company Overview

Altimmune, Inc. (NASDAQ: ALT) is a late clinical-stage biopharmaceutical company headquartered at 910 Clopper Road, Gaithersburg, Maryland, developing novel therapies for serious liver diseases. It is a smaller-reporting / non-accelerated filer with 57 full-time employees as of 2025-12-31, 16 of whom hold M.D. or Ph.D. degrees. It owns no manufacturing facilities — every gram of drug for trials and (eventually) commercial supply is outsourced to third-party CDMOs.

The entire enterprise is one molecule: pemvidutide (formerly ALT-801), a synthetic peptide that is a balanced 1:1 glucagon / GLP-1 dual receptor agonist. The 1:1 balance is the differentiation thesis: GLP-1 activation drives appetite suppression / weight loss and craving reduction, while glucagon-receptor activation acts directly on the liver to reduce fat, inflammation and fibrosis. Management asserts pemvidutide is "the only glucagon/GLP-1 dual receptor agonist with a balanced 1:1 potency," placing glucagon activity "on an even footing with GLP-1 activity."

Three lead indications, all liver-anchored:

• MASH (metabolic dysfunction-associated steatohepatitis) — the lead, now Phase 3-ready.
• AUD (alcohol use disorder) — Phase 2 (RECLAIM).
• ALD (alcohol-associated liver disease) — Phase 2 (RESTORE).

A fourth, obesity (MOMENTUM Phase 2, registrational program designed) exists but is strategically secondary — see Lens 3/12.

Business model & "payment terms": there is no product revenue and no commercial contract structure. The company has "not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues". It is financed by the issuance of equity (ATM + registered/underwritten offerings), a Hercules term loan, and historically grants/government contracts. The "customer," in effect, is the capital market until an approval and a commercial partner arrive. Customers.csv is empty — correct: a development-stage company has none.

Key counterparties / structure: lead asset is in-licensed — pemvidutide's core peptide-surfactant ("EuPort") IP is exclusively licensed from Mederis Diabetes, LLC. Pemvidutide entered Altimmune via the 2019 Spitfire Pharma acquisition, which carries a contingent $80M sales-milestone obligation payable on achieving specified worldwide net sales within ten years of FDA approval. An oral pemvidutide program is licensed via a Dec-2024 Adocia collaboration. So Altimmune does not wholly own its only asset outright — it sits atop a license + milestone stack.

Lens 2 · Supply Chain (→ CDMO / manufacturing, per +clinical)

For a fabless clinical-stage biotech the "supply chain" is the development and manufacturing value chain — and Altimmune is asset-light to the point of fragility on this axis. supply-chain.md is missing from the commercial layer, so this is built from the filings.

Upstream → company → end customer, with named stakeholders:

1. IP origin: Mederis Diabetes, LLC (licensor of the EuPort/peptide-surfactant composition IP) → Spitfire Pharma (acquired 2019, the vehicle that held pemvidutide; now a wholly-owned subsidiary, Spitfire Pharma, LLC) → Adocia S.A. (Dec-2024 collaborator for the oral formulation).
2. Drug substance / drug product: third-party contract manufacturers (CDMOs) — Altimmune has no facilities and "currently relies, and expects to continue to rely, on third parties for the manufacture of our product candidates" for both clinical and (if approved) commercial supply. Specific CDMO names are not disclosed in the 10-K — a genuine single-/limited-source risk the company itself flags.
3. Clinical execution: a global CRO "with deep experience running global MASH pivotal trials" has been selected for the PERFORMA Phase 3. Trial sites: ~15 US sites (RECLAIM/AUD), 34 US sites (RESTORE/ALD), global (PERFORMA/MASH).
4. Capital "suppliers": Hercules Capital (debt); Leerink, Piper Sandler, Stifel, Evercore, JMP, B. Riley (equity sales agents across the ATM programs).
5. End customer (future): patients via payers; realistically a large-pharma commercial partner or acquirer is the most probable route to market (see Lens 9 — the CEO is an M&A-proven liver-disease commercial operator).

Chokepoints / single-source dependencies: (a) the Mederis license — lose or breach it and the core composition IP is gone; (b) CDMO dependence — no in-house manufacturing means scale-up, comparability and supply-continuity risk for a peptide that must eventually be made at GLP-1-class volumes; (c) one molecule — there is no portfolio diversification anywhere in the chain. Names or it didn't happen: Mederis, Spitfire, Adocia, Hercules, Leerink/Piper/Stifel are the named nodes; the CDMO node is real but unnamed in the filing.

Lens 3 · Competitive Advantages (moats)

positioning.md / bottlenecks.md are missing, so moats are assessed from filings + ``.

The moat such as it exists is mechanistic + IP, not scale or brand.

• Differentiated mechanism (the real edge): the balanced 1:1 glucagon/GLP-1 profile gives a direct hepatic anti-fibrotic/anti-steatotic effect that pure GLP-1 drugs lack, plus class-leading lean-mass preservation — in the obesity MOMENTUM trial, 78.1% of weight lost was fat, 21.9% lean mass. As the field pivots from "how much weight" to "quality of weight loss" (muscle-sparing) and to liver-specific endpoints, this is a genuine, defensible scientific position.
• IP estate: "robust patent portfolio covering composition, formulation, methods of use and treatment with patent expiration dates extending into the 2040s". Concretely: Mederis composition patents to May 2032 / May 2035 (+ pending to 2041); MASH method-of-use to Jan 2039; company-owned (un-licensed) formulation, weight-loss, fatty-liver and CV patents pending to 2041 / 2043; AUD & ALD method patents pending to 2047. Long runway if granted — but much is "pending applications," not issued.
• Regulatory moat-lets: FDA Breakthrough Therapy Designation (MASH, Jan 2026) + Fast Track (MASH and AUD). These speed review and signal "substantial improvement over existing therapies."
• First-in-disease optionality: there are no approved therapies for ALD, and AUD pharmacotherapy is thin (Alkermes' Vivitrol + generics). If pemvidutide works in alcohol indications, it is plausibly first/best-in-class in a white space the big GLP-1 players are not prioritizing.

Bargaining power: essentially none today. Altimmune needs the capital market, needs CDMOs, and will need a commercial partner far more than any of them need Altimmune. Its leverage is entirely data-contingent — positive readouts convert "no leverage" into "auction dynamics." That is the whole game.

Verdict on moat: narrow but real on mechanism + liver-disease positioning; weak on everything that protects an operating company (scale, distribution, brand, switching costs). This is an asset moat, not a franchise moat.

Lens 4 · Segments

Not applicable in the operating sense — single segment, zero revenue. The 10-Q states the CODM "assesses the performance of the Company … based solely on net (loss) income," and the company "has not generated any revenue from the sale of any products". segments.csv is empty — correct.

The only meaningful "segmentation" is R&D spend by program, which reveals where management is putting money (a forward tell). Q1-2026 R&D by pemvidutide program:

Read: spend is rotating out of the now-complete MASH Phase 2b and into the alcohol franchise (AUD + ALD), with MASH Phase 3 (PERFORMA) start-up costs beginning to layer in. Geographically the company is US-centric (56 of 57 employees in the US; one in the UK) with global trial ambitions.

---

Phase B — Measure performance (swapped for +clinical)

Lens 5 · Pipeline by phase (replaces Earnings Result)

The asset table is the company. All four pemvidutide programs:

Pivotal efficacy already in hand (the data that matters):

MASH — IMPACT Phase 2b (212 biopsy-confirmed F2/F3 subjects, randomized 1:2:2 to 1.2 mg / 1.8 mg / placebo; published Lancet 2025 Dec 6):

• MASH resolution without worsening fibrosis (24 wk, ITT): 58.2% (1.2 mg) and 52.1% (1.8 mg) vs 19.9% placebo, p<0.0001 both — a very strong resolution signal.
• Fibrosis improvement without worsening MASH (24 wk, ITT biopsy): 32.6% / 35.7% vs 27.9% placebo — NOT statistically significant. ← the single most important bear fact in the entire dossier.
• Rescue via AI pathology: a supplemental AI-based read showed statsig fibrosis reduction (31% of 1.8 mg achieved ≥60% fibrosis reduction vs 8% placebo, p<0.001); ELF and LSM NITs statsig at both doses.
• 48-wk (no biopsy by design): statsig ELF (−0.49 / −0.58 vs +0.16, p<0.0001) and LSM (−3.04 / −3.97 vs −0.03) improvements, deepening from wk24; weight loss 4.5% / 7.5% vs 0.2% (no plateau at 1.8 mg).
• EASL 2026 (May, NEW): qFibrosis (HistoIndex digital pathology) ≥1-stage regression in 68.6% (1.2 mg) / 54.5% (1.8 mg) vs 29.6% placebo (p<0.001 / p=0.002) — a partial rehabilitation of the missed biopsy endpoint; qFibrosis added as a Phase 3 secondary endpoint.

Obesity — MOMENTUM Phase 2 (48 wk): mean weight loss 10.3% / 11.2% / 15.6% at 1.2 / 1.8 / 2.4 mg vs 2.2% placebo; >30% of the 2.4 mg arm achieved ≥20% weight loss; 78.1% of loss was fat / 21.9% lean (class-leading muscle preservation); no MACE signal.

Safety: favorable across 700+ exposed patients in 8 completed + 2 ongoing studies; MASH 2b discontinuation due to AEs <1% / 1.2% vs 2.4% placebo with no titration; no drug-related SAEs.

Tolerability/adherence is a genuine asset — lower dropout than placebo is unusual in this class.

Lens 6 · Earnings Calls / management focus (sentiment trend)

transcripts/ is empty, so this is ``. Management's consistent, escalating message across 2025→2026 has been: "Phase 3-ready, fully funded, derisking the alcohol franchise."

• Q1-2026 call (May 2026): headline was "strong cash position and Phase 3 MASH trial plans" — capital-raise-and-execute posture, leaning on the ~$535M pro-forma cash and the PERFORMA start.
• Tonal shift over the last ~4 prints: from "can we get the MASH biopsy endpoint?" (June 2025, post-miss, stock −59%) → "Breakthrough Therapy + EoP2 aligned, we're going to Phase 3" (Jan 2026) → "fully financed through the catalysts, AUD topline imminent" (Q1-2026). The story has migrated from data-anxiety to execution-and-optionality.
• What they now say a lot: "differentiated," "lean mass preservation," "class-leading tolerability," "serious liver diseases," "fully funded into [late-decade]." What they stopped emphasizing: head-to-head weight-loss magnitude vs Lilly/Novo — a tacit acknowledgment they don't win that race, so they reframed the contest around liver biology and body composition.

Lens 7 · Catalyst calendar + mechanism comps (replaces P/E comps)

Comparables are by mechanism/target, not by multiple — pre-revenue, so EV/Sales is meaningless for ALT itself.

Catalyst calendar:

Mechanism comps (the competitive set that actually matters):

The comp table indicts the weight-loss thesis and supports the liver thesis. On the metric retail cares about (pounds), pemvidutide is mid-pack at best. On the metric the liver indication rewards (direct glucagon-driven fibrosis/steatosis effect + muscle-sparing), it is genuinely differentiated. The bet is that MASH/ALD/AUD reward the latter.

Lens 8 · Stock-Price Catalysts (what moves ALT >5%)

Mostly ``; the tape says ALT is a pure binary-event stock with violent moves:

• 2025-06-26: −59% in a single session ($7.71 → $3.18) on IMPACT 24-wk topline — despite a crushing MASH-resolution win — because the biopsy-fibrosis endpoint missed statistical significance. This is the defining tape event: the market punished the miss and ignored the resolution beat. It tells you (a) expectations were high, (b) fibrosis is the endpoint the market scores, (c) the float is jumpy.
• 2026-01-05: Breakthrough Therapy Designation (MASH) — positive catalyst, helped stabilize the post-crash range.
• 2025-12-01: CEO succession announced — "stock falls after CEO Garg announces 2026 departure" — a leadership-uncertainty dip.
• 2026-04: $211M raise at $3.00 — dilutive but de-risking; removed the "can they fund Phase 3?" overhang.
• 2026-05-27/28: EASL qFibrosis data — incremental positive (digital-pathology fibrosis win).

Pattern: ALT reacts to (1) MASH efficacy endpoints — especially fibrosis, (2) regulatory designations, (3) financing/dilution events, (4) management. It is not macro-driven; it is a clinical-catalyst instrument. With 21% short interest (below), every positive binary is a squeeze candidate and every miss is a trapdoor.

---

Phase C — Judge people & books

Lens 9 · Management

The most important recent development at this company is the CEO change — and it is a tell.

• Jerry (Jerome) Durso — CEO effective 2026-01-01 (was Board Chair; succeeded Vipin Garg, Ph.D., who ran ALT for 7 years and stays as advisor through 2026-06-30). Track record: 30+ years commercial/operations; most recently CEO of Intercept Pharmaceuticals — the company that pioneered the NASH/MASH category (Ocaliva) — which he "transformed … and ultimately led through its successful acquisition by Alfasigma." Before that, COO of Intercept (2017-21) and 20+ years at Sanofi (Chief Commercial Officer, Global Diabetes Division; CCO US Pharma).
• Why this matters / archetype: Garg = the scientist-builder who took pemvidutide from preclinical to Phase 3-ready. Durso = a commercial + M&A operator specialized in serious liver disease, who has personally sold a liver-disease company. Installing him precisely as the asset goes Phase 3 and the alcohol data reads out is a strong signal that the end-game is a partnership or sale, not a solo commercial launch. For a single-asset clinical biotech that is arguably the right archetype and a point in the bull column.
• Tenure & skin in the game: Durso brand-new in the seat; Garg departing. Insider-ownership detail not in insider-transactions.csv (absent) and not quantified in the read — n/a for precise insider %. Board recently added commercial heavyweights (Teri Lawver, ex-J&J), consistent with commercial-readiness intent.
• Capital-allocation history: disciplined for a biotech — they raised opportunistically into strength (April $3.00 raise after the BTD), secured a $125M Hercules facility as non-dilutive backstop, and funded through the catalysts before initiating an expensive Phase 3. R&D actually fell 19% in 2025 ($66.4M) as the 2b wound down — not a company burning indiscriminately. No buybacks/dividends (correct — pre-revenue).
• Red flags: (1) $0.6M severance to a departing executive in Q1-2026 and an option-modification charge — minor, but executive churn alongside the CEO change bears watching; (2) relentless dilution (Lens 10/13) is shareholder-unfriendly even when necessary; (3) the asset is licensed-in (Mederis) with an $80M Spitfire milestone — not fully owned.

Net: a credible, commercially- and M&A-savvy management transition that improves the exit probability. The hire of an ex-Intercept CEO is the single most bullish soft-signal in the file.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst — but note: a pre-revenue biotech has no revenue to recognize aggressively, so the classic income-statement games don't apply. The forensic risks here are dilution, going-concern, debt covenants, and SBC, not channel-stuffing.

• Going concern: financial statements are prepared on a going-concern basis and explicitly note they exclude adjustments that would be needed "should the Company be unable to continue as a going concern". Management asserts ≥12 months of runway from the Q1-2026 cash + April raise. No going-concern qualification — but the boilerplate is present, as always for development-stage names.
• Dilution — the real red flag: shares outstanding went 70.7M (Dec-2023) → 130.2M (Mar-31-2026) → 194.5M (May-8-2026) — roughly +175% in ~2.3 years. Authorized share count was doubled 200M → 400M (April 2026 charter amendment). The April offering layered in 75M warrants at $3.00 (potential +$225M / +75M shares) on top. This is the dominant value-leakage vector. Accumulated deficit $672.0M.
• Debt / covenants: Hercules term loan — $125M facility, $35M drawn, 13.37% weighted-effective rate, IO through ~Dec-2027 (extendable to Dec-2028), matures Jan-2029, secured by substantially all assets, 6.25% end-of-term charge. Critically, the financial covenant is conditionally waived once market cap > $800M — at the current ~$564M market cap the company is inside the covenant regime, a subtle pressure point (a sustained low cap keeps the covenant live and the lien tight). In compliance as of Q1-2026.
• SBC: $3.4M in Q1-2026 (down from $4.0M) — modest and not flattering any non-GAAP metric (there's no non-GAAP profit to flatter). $20.6M unrecognized option cost + $7.9M unrecognized RSU cost overhang.
• Cash vs earnings: operating cash burn $20.9M in Q1-2026 (vs $22.6M net loss — clean, no suspicious accrual divergence); FY2025 net loss $88.1M on R&D $66.4M + G&A $28.1M. Interest income ($2.9M/qtr) is now a real offset to burn given the large cash pile.
• Impairment: a $0.7M ROU/leasehold impairment in Q1-2026 (office/lab lease being subleased) — they're shrinking physical footprint, consistent with the fabless model.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None. "No LR found for this company" via EDGAR EFTS, 2021-06-18 → 2026-06-18.
• SEC AAERs: None. "No AAER found".
• Non-SEC (FTC/DOJ/FDA/CFPB) web search: no material enforcement actions, consent decrees, fines or penalties surfaced for Altimmune in the searches run for this dossier. FDA interactions are favorable (Breakthrough, Fast Track, EoP2 alignment), not enforcement.
• Item 3 / Item 1 Legal Proceedings (company's own disclosure): the Q1-2026 10-Q states it "may be involved in various legal proceedings" generically; Note 10 confirms disputes "none of which are currently reasonably possible or probable of material loss". No material litigation disclosed.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-Q legal-proceedings disclosure as of 2026-06-18.

---

Phase D — Project & stress-test

Lens 11 · rNPV + runway-to-catalyst (replaces EPS projection)

EPS projection is the wrong tool — Altimmune will not have positive EPS for years. The +clinical lens asks two questions: what is the risk-adjusted value of the asset, and does cash reach the next value-inflection?

Runway (the question that actually matters) — answered: YES, comfortably.

• Q1-2026 cash + ST investments: $331.6M.
• • April 2026 raise: $211.2M net → ~$535M pro forma end-April.
• Annual cash burn ≈ $85–90M (FY2025 net loss $88.1M; Q1-26 operating burn $20.9M × 4 ≈ $84M, partly offset by ~$11M/yr interest income).
• Implied runway: into ~2028 — past the Q3-2026 AUD topline, past PERFORMA initiation, and well toward the Phase 3 interim. Plus $90M undrawn Hercules tranches and $165M remaining ATM capacity and a potential $225M warrant exercise. Financing risk is, unusually for a clinical biotech, largely off the table for 2026-27. This is the single strongest line in the bull case.

rNPV of the lead asset (illustrative, every input ``):

• MASH (lead): MASH is a multi-$10B TAM; Rezdiffra alone is already >$1.1B TTM and growing 127%. Assume pemvidutide peak US/EU MASH sales of ~$1.5–2.5B if approved. Apply a Phase-3-entry PoS of ~30% (BTD helps; but the biopsy-fibrosis miss and a 60-month trial with 2029 interim weigh against) and a high biotech discount rate (~12%) over a long horizon → a risk-adjusted MASH value of very roughly $0.5–1.0B.
• AUD + ALD: earlier-stage, white-space, smaller TAM but less competition and a near-term readout; assign modest option value, mostly captured in the Q3-2026 binary.
• Obesity: deprioritized; treat as call option, near-zero in base case.
• Cross-check vs market: ALT's ~$564M market cap sits at the low end of a plausible MASH-only rNPV and effectively ascribes near-zero value to AUD/ALD/obesity and to the strategic/M&A premium. That is the asymmetry the bulls are buying.

Brier forecast to log (the binary that matters, not an EPS line): "ALT — RECLAIM (AUD) Phase 2 meets its primary endpoint (statsig reduction in heavy drinking days at wk24), topline by 2026-09-30, p≈0.45." [NOT logged — breadth --watchlist loop skips forecast.ts create; recorded here for a later /thesis pass.]

Lens 12 · Bull vs Bear

Bull case. Altimmune is a fully-funded, derisked, single-asset optionality vehicle trading at the low end of its own MASH rNPV with three free shots on goal layered on top. The MASH-resolution data (58%/52% vs 20%) is among the best in the class; the qFibrosis digital-pathology win (68.6%/54.5% vs 29.6%) materially rehabilitates the one blemish and is now a Phase 3 secondary endpoint; Breakthrough Therapy + FDA EoP2 alignment de-risk the regulatory path. The glucagon-driven liver mechanism + class-leading lean-mass preservation is exactly the differentiation the market is rotating toward as "quality of weight loss" and liver-specific endpoints displace raw tonnage. AUD (Q3-2026) and ALD are near-term, low-competition, potentially first/best-in-class readouts the market is paying ~nothing for. And the installation of an ex-Intercept CEO who sold a liver-disease company points the whole thing at a partnership or acquisition — the most likely path to a multiple of today's price. With 21% short interest, any positive binary is a squeeze. Analyst consensus ~$16–17.67 vs ~$2.94 frames the asymmetry: ~5-6× upside if even one leg derisks.

Bear case (2–3 permanent-impairment risks). (1) The drug is a mediocre weight-loss agent in a weight-loss world — 7.5% (MASH dose) / 15.6% (obesity top dose) vs survodutide 16.6%, sema ~15%, tirzepatide ~22%; if MASH approval ultimately tracks weight/metabolic benefit, pemvidutide is structurally behind, and its direct mechanistic twin (survodutide) is ahead on data, stage-parity, and balance sheet. (2) The biopsy-fibrosis endpoint already missed once (−59% day) — Phase 3 must hit histologic fibrosis on biopsy at the 52-week interim; NIT/AI wins are supportive, not a substitute, and the FDA accelerated-approval gate is biopsy-based. A second fibrosis miss in 2029 is an extinction event for the thesis. (3) Relentless dilution — +175% shares in 2.3 years, authorized doubled to 400M, 75M warrants struck at $3.00 — means even a good outcome is shared across a vastly larger base; per-share upside is structurally taxed. Expectations baked into price: the ~$564M cap already requires you to believe MASH Phase 3 works and the asset gets partnered/sold; it is not "cheap optionality," it is "fair optionality with real binary risk."

Pre-mortem (18 months out, thesis broke — what happened?): RECLAIM AUD topline (Q3-2026) missed — pemvidutide reduced weight but not heavy-drinking days — collapsing the "alcohol franchise" leg that justified the optionality premium; simultaneously, survodutide's LIVERAGE MASH Phase 3 read out positive first, anchoring the glucagon/GLP-1-in-liver narrative to Boehringer; ALT, needing to fund a 60-month Phase 3 alone with a sub-$800M cap (covenant live), tapped the ATM and warrants into weakness, and the stock re-based below $2 on dilution + competitive displacement.

Multiples too high? Inapplicable (no earnings). On rNPV the stock is fair-to-slightly-cheap, not egregiously either way — the upside is event-driven, not re-rating-driven.

Contrarian view (what the market refuses to see): the market is still scoring ALT as a failed-fibrosis weight-loss also-ran, when the actual asset is a liver-disease platform with a first-in-class shot at AUD/ALD run by a man who builds and sells liver-disease companies. The mispricing, if there is one, is that the alcohol franchise and the M&A endgame are in the price at ~zero.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the model: pemvidutide is one licensed-in molecule in the single most competitive therapeutic arena in biopharma, against Lilly, Novo, Boehringer, Roche, Madrigal, Viking — every one of which has more money, more data, or both. Altimmune's entire value is contingent on out-executing better-capitalized incumbents with a drug that is not best-in-class on the headline metric.
• Concentration: 100% of value is one asset, and within that, disproportionately one indication (MASH) gated on one biopsy endpoint that has already failed once. There is no diversification anywhere.
• Why the moat is weaker than bulls think: "only balanced 1:1 glucagon/GLP-1" is a marketing distinction, not a barrier — survodutide is also a glucagon/GLP-1 dual agonist, further along in MASH Phase 3, with 16.6% weight loss and a Boehringer balance sheet. "Differentiated lean-mass preservation" is real but unproven as a commercial or regulatory differentiator. Much of the IP is pending, not issued, and the core composition IP is licensed from Mederis (not owned) with an $80M Spitfire milestone layered on.
• Most dangerous underestimated competitor: survodutide (Boehringer/Zealand) — same mechanism, ahead on stage and weight loss, infinitely better funded. If LIVERAGE reads out first and positive, pemvidutide's mechanistic story is commoditized by a giant.
• Worst capital-allocation reality: serial, heavy dilution into a doubled authorized share count + 75M warrants at $3 — management is funding a 60-month trial by continuously issuing equity, and the <$800M-cap covenant keeps Hercules's lien on all assets live.
• Assumptions that must hold for today's ~$2.94: (a) MASH Phase 3 hits histologic fibrosis on biopsy at the 2029 interim; (b) at least one alcohol indication works; (c) a partner/acquirer materializes before the cash and patient-capital run out; (d) survodutide/sema don't render the niche moot. Remove any one and the equity is impaired.
• If growth/PoS disappoints by 20-30%: there is no "growth" to disappoint — there is a coin-flip that either pays multiples or goes toward zero. A negative AUD topline in Q3-2026 alone could take 30-50% off the equity overnight (cf. the −59% biopsy-miss precedent).
• Single scenario that permanently impairs: PERFORMA 52-week biopsy interim (~2029) fails fibrosis — a repeat of the 2b miss at registrational scale — which would terminate the MASH program and, with it, the bulk of the company's value. Plausibility: non-trivial, given the asset has already missed biopsy fibrosis once.

Lens 14 · Management Questions (ordered by information value)

1. PERFORMA is gated on a 52-week biopsy fibrosis interim — given IMPACT's biopsy-fibrosis miss at 24 weeks, what specifically (dose, duration, population enrichment, statistical design) changes your probability of hitting histologic fibrosis at registrational scale?
2. RECLAIM AUD topline is due Q3-2026 — what magnitude of reduction in heavy-drinking-days would you consider a clear win, and is it powered to deliver statistical significance at ~100 subjects?
3. With the CEO now an ex-Intercept executive who sold a liver-disease company, is the explicit strategy to partner or sell pemvidutide, and at what data milestone do you expect to run that process?
4. How do you position pemvidutide commercially against survodutide — the same glucagon/GLP-1 mechanism, further along in MASH Phase 3, with materially greater weight loss and Boehringer's resources?
5. The Hercules covenant is only waived above an $800M market cap; at the current ~$560M cap, what financial covenants are live, and what is your headroom?
6. You doubled authorized shares to 400M and issued 75M warrants at $3.00 — what is your maximum tolerable dilution to reach a MASH approval, and under what conditions would you draw the remaining Hercules tranches instead of equity?
7. Obesity MOMENTUM showed 15.6% weight loss at 2.4 mg — why deprioritize a registrational obesity program when that is where the capital and TAM are, and what would re-activate it?
8. What is the realistic peak-sales case for pemvidutide in MASH given Rezdiffra is entrenched and semaglutide is at the FDA with a Phase 3 fibrosis win?
9. The asset is licensed from Mederis with an $80M Spitfire sales milestone — walk us through the full royalty/milestone economics that sit between net sales and Altimmune's net cash.
10. Manufacturing is entirely outsourced and you name no CDMO — how de-risked is peptide drug-substance supply at commercial (GLP-1-class) scale, and is dual-sourcing in place?
11. ALD has no approved therapy — if RESTORE is positive, what is the regulatory path and timeline to a first-in-disease label, and how big is that opportunity standalone?
12. The Adocia oral pemvidutide collaboration — where does an oral formulation sit in priority versus the injectable, and what is the development timeline?
13. What did the FDA actually agree to at the End-of-Phase-2 meeting regarding accelerated approval, and what is the confirmatory-evidence burden (liver-related outcomes over ~60 months)?
14. With Garg departing and at least one executive exit (severance booked in Q1-2026), how stable is the senior R&D/clinical team carrying PERFORMA?
15. What insider buying has occurred at these prices, and how is management compensation tied to per-share (dilution-adjusted) value creation rather than milestones alone?

---